(Q37532013)

20 August 2017

1 reference

title

High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases (English)

1 reference

20 August 2017

3

Detlef Zillikens

1 reference

20 August 2017

2

Takashi Hashimoto

1 reference

20 August 2017

Norito Ishii

1

1 reference

PubMed ID

19557317

20 August 2017

Ralf J Ludwig

series ordinal

4

1 reference

20 August 2017

1 April 2010

1 reference

Clinical Reviews in Allergy & Immunology

20 August 2017

1 reference

20 August 2017

38

1 reference

20 August 2017

2-3

1 reference

20 August 2017

186-195

1 reference

https://scigraph.springernature.com/pub.10.1007/s12016-009-8153-y

20 August 2017

0 references

cites work

Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8153-Y

Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8153-Y

Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8153-Y

Synthetic autoantigens of immunoglobulins and T-cell receptors: their recognition in aging, infection, and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12016-009-8153-Y

Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins

21 January 2018

1 reference

12 December 2020

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

1 reference

12 December 2020

Emerging treatment for epidermolysis bullosa acquisita

1 reference

12 December 2020

Management of autoimmune bullous diseases: pharmacology and therapeutics

1 reference

12 December 2020

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

1 reference

12 December 2020

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

1 reference

12 December 2020

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

1 reference

12 December 2020

IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy

1 reference

12 December 2020

IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris

1 reference

12 December 2020

Intravenous immune globulin: fighting antibodies with antibodies

1 reference

12 December 2020

High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases

1 reference

12 December 2020

Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients

1 reference

12 December 2020

Use of intravenous gamma globulins in neuroimmunologic diseases.

1 reference

12 December 2020

Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment

1 reference

12 December 2020

Bullous pemphigoid: physiopathology, clinical features and management.

1 reference

12 December 2020

Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins.

1 reference

12 December 2020

Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice

1 reference

12 December 2020

Identification of a receptor required for the anti-inflammatory activity of IVIG.

1 reference

12 December 2020

The role of IVIg treatment in severe pemphigus vulgaris.

1 reference

12 December 2020

Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

1 reference

12 December 2020

P-selectin: a common therapeutic target for cardiovascular disorders, inflammation and tumour metastasis

1 reference

12 December 2020

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

12 December 2020

Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy

1 reference

12 December 2020

Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors

1 reference

12 December 2020

[Bullous autoimmune dermatoses (I): Pathogenesis and diagnosis]

1 reference

12 December 2020

Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases

1 reference

12 December 2020

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

1 reference

12 December 2020

Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins

1 reference

12 December 2020

Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.

1 reference

12 December 2020

A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders

1 reference

12 December 2020

Use of intravenous immunoglobulin therapy in autoimmune blistering diseases

1 reference

12 December 2020

Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin

1 reference

12 December 2020

Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome.

1 reference

12 December 2020

Immune thrombocytopenic purpura

1 reference

12 December 2020

The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model

1 reference

12 December 2020

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

1 reference

12 December 2020

High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris

1 reference

12 December 2020

Psoriasis improved by intravenous immunoglobulin therapy

1 reference

12 December 2020

Treatment of pemphigus with intravenous immunoglobulin

1 reference

12 December 2020

Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus.

1 reference

12 December 2020

Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris

1 reference

12 December 2020

F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

1 reference

12 December 2020

Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes

1 reference

12 December 2020

Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view

1 reference

12 December 2020

High-dose intravenous immunoglobulin treatment of multiple sclerosis

1 reference

12 December 2020

Epidermolysis bullosa acquisita: diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin

1 reference

12 December 2020

Adverse events associated with intravenous immunoglobulin therapy

1 reference

12 December 2020

Rituximab in treatment-resistant autoimmune blistering skin disorders

1 reference

12 December 2020

Guidelines for the management of pemphigus vulgaris

1 reference

12 December 2020

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

1 reference

12 December 2020

Lymphocyte homing and homeostasis

1 reference

12 December 2020

Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]

1 reference

12 December 2020

Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses

1 reference

12 December 2020

The new pemphigus variants

1 reference

12 December 2020

Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody

1 reference

12 December 2020

1 reference

12 December 2020

Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy

1 reference

12 December 2020

Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model

1 reference

12 December 2020

Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita

1 reference

12 December 2020

Skin diseases related to abnormality in desmosomes and hemidesmosomes--editorial review

1 reference

12 December 2020

1 reference

12 December 2020

Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis

1 reference

12 December 2020

Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins

1 reference

12 December 2020

Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases

1 reference

12 December 2020

Epidermolysis bullosa acquisita: update and review

1 reference

12 December 2020

Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia.

1 reference

12 December 2020

The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease

1 reference

12 December 2020

The use of i.v. IG therapy in dermatology

1 reference

12 December 2020

Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation.

1 reference

12 December 2020

Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease

1 reference

12 December 2020

IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity

1 reference

12 December 2020

Idiotypic and anti-idiotypic elastin autoantibodies: Implications for IVIg and pregnancy loss.

1 reference

12 December 2020

Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus

1 reference

12 December 2020

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid

1 reference

12 December 2020

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita

1 reference

12 December 2020

Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus

1 reference

12 December 2020

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

1 reference

12 December 2020

High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid

1 reference

12 December 2020

High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders

1 reference

12 December 2020

Cicatricial pemphigoid treated with intravenous immunoglobulin

1 reference

12 December 2020

Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations--possible immunomodulation of atherosclerosis

1 reference

12 December 2020

Epidermolysis bullosa acquisita and multiple myeloma

1 reference

12 December 2020

Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy?

1 reference

12 December 2020

Effective treatment of experimental autoimmune neuritis with Fc fragment of human immunoglobulin

1 reference

12 December 2020

Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.

1 reference

12 December 2020

Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid

1 reference

12 December 2020

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

1 reference

12 December 2020

Immune cell migration in inflammation: present and future therapeutic targets

1 reference

12 December 2020

PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-selectin functions.

1 reference

12 December 2020

Increased in vivo antibody activity against interferon alpha, interleukin-1alpha, and interleukin-6 after high-dose Ig therapy

1 reference

12 December 2020

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris

1 reference

12 December 2020

Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy

1 reference

12 December 2020

Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity

1 reference

12 December 2020

Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin

1 reference

12 December 2020

Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris

1 reference

12 December 2020

Treatment strategies for pemphigus vulgaris in Japan

1 reference

12 December 2020

[Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins]

1 reference

12 December 2020

Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody

1 reference

12 December 2020

Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin

1 reference

12 December 2020

Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy

1 reference

12 December 2020

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

1 reference

12 December 2020

Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study

1 reference

12 December 2020

High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.

1 reference

12 December 2020

Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins

1 reference

12 December 2020

Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins

1 reference

12 December 2020

The biology and action of colony stimulating factor-1

1 reference

12 December 2020

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

1 reference

12 December 2020

Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins

1 reference

12 December 2020

Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes

1 reference

12 December 2020

Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up

1 reference

12 December 2020

10.1007/S12016-009-8153-Y

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19557317